After the books closed: the quarter's biggest news happened too late to be in the numbers
The model's full reasoning — Q3 2016 call → NOThe question asks whether management reports that the most important positive developments happened so late in the period or shortly after it ended that the results contain little or none of their effect, with management marking the timing. Looking at the transcript, the key positive developments mentioned: - SPN-812 Phase 2b positive top-line results announced in October (after Q3 ended) - FDA tentative approval for Trokendi XR migraine indication during Q3 For SPN-812: The results were announced in October, which is after the Q3 period ended (September 30). Management says "we announced in October positive top line results from our Phase 2-B clinical trial." This is a concrete positive development that occurred after the quarter ended. Does management treat this as the real story the numbers missed? Management discusses the SPN-812 results extensively, calling them "truly remarkable" and discussing plans for Phase 3. However, SPN-812 is a pipeline product - it's not generating revenue. The reported results (net product sales) are for Trokendi XR and Oxtellar XR. The question asks about "results being presented" - the financial results. The SPN-812 data doesn't affect the financial results at all. It's a clinical trial result, not a business development that would show up in revenue. For the Trokendi XR migraine indication: "during the third quarter of 2016, the FDA granted a tentative approval to our supplemental new drug application" - this was during the quarter, and management says they "will be ready to launch the migraine indication soon after receiving full FDA approval." But this is still pending full approval - it's not yet converted into business. The question asks whether management conveys that because of timing, the reported results reflect little or none of these developments. The SPN-812 data doesn't impact financial results at all - it's a pipeline milestone. The migraine approval is still tentative, not full approval, so it hasn't converted into business yet. Management doesn't seem to be saying "our results don't reflect these late developments" in a way that suggests the results are missing the real story. The financial results are driven by Trokendi XR and Oxtellar XR sales, which are growing well.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| SWBI | Smith & Wesson Brands, Inc. | Q1 2023 | 2022-09-08 | C+ |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| BFI | BurgerFi International, Inc. | Q3 2021 | 2021-11-12 | C |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
OPK · Q1 2022 → YESThe question is: Does management report that the MOST IMPORTANT POSITIVE DEVELOPMENTS of the period happened SO LATE IN THE REPORTED PERIOD, OR SHORTLY AFTER IT ENDED, that the results being presented...YES The transcript shows management treating the ModeX acquisition (announced and closed on the call date, May 9) and the Sema4/GeneDx deal (closed April 29) as major positive developments that occurred after the Q1 period ended. These are framed as key steps toward unlocking value and are highlighted as the "exciting announcement" that changed the call format.
RNW · Q2 2022 → YESThe question is: Does management report that the MOST IMPORTANT POSITIVE DEVELOPMENTS of the period happened SO LATE IN THE REPORTED PERIOD, OR SHORTLY AFTER IT ENDED, that the results being presented...YES The transcript shows management explicitly marking the timing of key positive developments: 400 MW commissioned "since the end of the quarter" (bringing operating capacity to 7 GW today, with another 400 MW scheduled "over the next couple of weeks"), plus the completed Telangana acquisition adding 260 MW.
ASM · Q4 2023 → YESThe question is: Does management report that the MOST IMPORTANT POSITIVE DEVELOPMENTS of the period happened SO LATE IN THE REPORTED PERIOD, OR SHORTLY AFTER IT ENDED, that the results being presented...